Tearsheet

Gyrodyne (GYRO)


Market Price (1/15/2026): $9.1 | Market Cap: $1.3 Mil
Sector: Real Estate | Industry: Real Estate Services

Gyrodyne (GYRO)


Market Price (1/15/2026): $9.1
Market Cap: $1.3 Mil
Sector: Real Estate
Industry: Real Estate Services

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.


0 Low stock price volatility
Vol 12M is 46%
Weak multi-year price returns
2Y Excs Rtn is -49%, 3Y Excs Rtn is -71%
Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -2.7 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -50%
1   Debt is significant
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 346%
2   Weak revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -1.2%, Rev Chg QQuarterly Revenue Change % is -1.8%
3   Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -44%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -44%
4   Key risks
GYRO key risks include [1] a multi-year lack of revenue growth and stagnant earnings, Show more.
0 Low stock price volatility
Vol 12M is 46%
1 Weak multi-year price returns
2Y Excs Rtn is -49%, 3Y Excs Rtn is -71%
2 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -2.7 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -50%
3 Debt is significant
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 346%
4 Weak revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -1.2%, Rev Chg QQuarterly Revenue Change % is -1.8%
5 Not cash flow generative
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -44%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -44%
6 Key risks
GYRO key risks include [1] a multi-year lack of revenue growth and stagnant earnings, Show more.

Valuation, Metrics & Events

GYRO Stock


Why The Stock Moved


Qualitative Assessment

AI Analysis | Feedback

Here are the key points for the approximate -9.5% movement in Gyrodyne's (GYRO) stock from October 31, 2025, to January 15, 2026:

1. Amendment to Flowerfield Property Sale Agreement. Gyrodyne, LLC amended its purchase and sale agreement with B2K Smithtown LLC for the Flowerfield property on January 6, 2026. This amendment included a $1,520,222 credit to the buyer for on-site improvements, and the buyer assumed responsibility for common facilities and offsite work. Gyrodyne is still reviewing the impact of this credit on the overall value of the Flowerfield property and its net assets in liquidation.

2. Uncertainty Regarding Property Covenants. The amended Flowerfield sale agreement also set a deadline of February 5, 2026, for the parties to resolve certain third-party land use covenants. If an agreement is not reached, B2K Smithtown LLC retains the right to terminate the agreement by February 6, 2026, and receive a return of its deposit, adding uncertainty to the sale's finalization and impact on Gyrodyne's liquidation value.

Show more

Stock Movement Drivers

Fundamental Drivers

null
null

Market Drivers

10/31/2025 to 1/14/2026
ReturnCorrelation
GYRO-9.5% 
Market (SPY)1.2%11.0%
Sector (XLRE)1.2%-17.4%

Fundamental Drivers

null
null

Market Drivers

7/31/2025 to 1/14/2026
ReturnCorrelation
GYRO5.7% 
Market (SPY)9.5%14.6%
Sector (XLRE)0.7%17.5%

Fundamental Drivers

null
null

Market Drivers

1/31/2025 to 1/14/2026
ReturnCorrelation
GYRO-1.0% 
Market (SPY)15.7%7.0%
Sector (XLRE)2.3%4.4%

Fundamental Drivers

null
null

Market Drivers

1/31/2023 to 1/14/2026
ReturnCorrelation
GYRO0.1% 
Market (SPY)76.2%4.3%
Sector (XLRE)11.9%8.1%

Return vs. Risk


Price Returns Compared

 202120222023202420252026Total [1]
Returns
GYRO Return-29%-30%23%-10%2%-2%-44%
Peers Return6%-15%11%24%33%2%67%
S&P 500 Return27%-19%24%23%16%2%85%

Monthly Win Rates [3]
GYRO Win Rate42%33%58%33%33%0% 
Peers Win Rate48%43%58%67%62%80% 
S&P 500 Win Rate75%42%67%75%67%100% 

Max Drawdowns [4]
GYRO Max Drawdown-35%-30%-4%-23%-17%-2% 
Peers Max Drawdown-12%-27%-18%-15%-4%-1% 
S&P 500 Max Drawdown-1%-25%-1%-2%-15%0% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: WELL, VTR, MPW, OHI, SBRA.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 1/14/2026 (YTD)

How Low Can It Go

Unique KeyEventGYROS&P 500
2022 Inflation Shock2022 Inflation Shock  
2022 Inflation Shock% Loss% Loss-54.4%-25.4%
2022 Inflation Shock% Gain to Breakeven% Gain to Breakeven119.2%34.1%
2022 Inflation ShockTime to BreakevenTime to BreakevenNot Fully Recovered days464 days
2020 Covid Pandemic2020 Covid Pandemic  
2020 Covid Pandemic% Loss% Loss-25.3%-33.9%
2020 Covid Pandemic% Gain to Breakeven% Gain to Breakeven33.8%51.3%
2020 Covid PandemicTime to BreakevenTime to BreakevenNot Fully Recovered days148 days
2018 Correction2018 Correction  
2018 Correction% Loss% Loss-25.3%-19.8%
2018 Correction% Gain to Breakeven% Gain to Breakeven33.9%24.7%
2018 CorrectionTime to BreakevenTime to BreakevenNot Fully Recovered days120 days
2008 Global Financial Crisis2008 Global Financial Crisis  
2008 Global Financial Crisis% Loss% Loss-71.1%-56.8%
2008 Global Financial Crisis% Gain to Breakeven% Gain to Breakeven245.7%131.3%
2008 Global Financial CrisisTime to BreakevenTime to Breakeven487 days1,480 days

Compare to WELL, VTR, MPW, OHI, SBRA

In The Past

Gyrodyne's stock fell -54.4% during the 2022 Inflation Shock from a high on 4/9/2021. A -54.4% loss requires a 119.2% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Gyrodyne (GYRO)

Gyrodyne, LLC. owns, leases and manages diverse commercial properties. The firm is distinguished by its service-oriented philosophy toward property ownership and management. Gyrodyne has grown from a largely Long Island player during the past into a diversified East Coast presence with an emphasis on medical office product.

AI Analysis | Feedback

A micro-cap Howard Hughes Corporation (HHC), focused on monetizing a small portfolio of legacy real estate assets.

AI Analysis | Feedback

  • Real Estate Portfolio Management: Ownership and management of a significant land parcel located in St. James, New York.
  • Land Development and Sales: Strategic planning for the development and eventual sale of their real estate holdings.

AI Analysis | Feedback

Gyrodyne (symbol: GYRO) has undergone significant changes in its business model. Historically, Gyrodyne operated as a real estate investment trust (REIT) that owned, managed, and leased commercial properties, primarily medical office and industrial spaces, located on Long Island, New York.

As such, its major customers were the *businesses* and *organizations* that leased space within its properties. The company sold primarily to other companies. Due to the nature of a REIT's operations, which typically involve numerous tenants rather than a few major ones, specific individual major customer names were not publicly disclosed. However, the categories of companies that were its tenants included:

  • Healthcare Providers: Medical practices, clinics, laboratories, and other healthcare organizations leasing its medical office buildings.
  • Industrial Businesses: Companies involved in manufacturing, distribution, warehousing, and other light industrial activities that leased space in its industrial parks.

It is important to note that Gyrodyne has largely completed the sale of its real estate assets in recent years (e.g., by the end of 2021). As a result, the company no longer has tenants as its primary customers and is in the process of winding down its operations and distributing capital to shareholders.

AI Analysis | Feedback

null

AI Analysis | Feedback

Gary J. Fitlin, Chief Executive Officer, President, Chief Financial Officer and Treasurer

Mr. Fitlin has served as Gyrodyne, LLC's Chief Executive Officer and President since May 1, 2017, and as Chief Financial Officer and Treasurer since joining the company in October 2009. From August 2012 to February 2013, he also served as interim President and Chief Executive Officer. Prior to joining Gyrodyne, he was the Director of Accounting Implementation for Lexington Realty Trust, a publicly traded real estate investment trust on the NYSE, from July 2006 to March 2008, where he was responsible for mergers and acquisitions. Before that, he held senior financial officer positions at various publicly traded companies, overseeing mergers and acquisitions, global accounting, management reporting, tax compliance and planning, financial systems, risk management, and contract administration. Mr. Fitlin is a Certified Public Accountant and an alumnus of Arthur Andersen & Co., holding a BS degree in Accounting and Economics from the State University of New York at Oswego.

Peter Pitsiokos, Executive Vice President, Chief Operating Officer, Chief Compliance Officer and Corporate Secretary

Mr. Pitsiokos has been with Gyrodyne, LLC since December 2003, initially serving as Chief Compliance Officer and Chief Operating Officer. His current roles include Executive Vice President, Chief Operating Officer, Chief Compliance Officer, and Corporate Secretary.

Dawn Ibraham, Controller

Ms. Ibraham has served as the Controller for Gyrodyne, LLC since joining the company in December 2012.

AI Analysis | Feedback

The key risks to Gyrodyne (GYRO) primarily stem from its business operations in the real estate sector and its financial performance:

  1. Lack of Revenue Growth and Stagnant Earnings: Gyrodyne has reported no revenue growth over the past year, and its earnings per share (EPS) remain stagnant. This indicates significant challenges in the company's profitability and overall operational efficiency. The company's business performance has been characterized by a lack of revenue growth over the past one, three, or five years, highlighting difficulties in expanding its operations and capitalizing on market opportunities.
  2. Real Estate Market Volatility and Economic Downturns: As a real estate company focused on owning and managing industrial and medical office buildings, Gyrodyne is inherently exposed to sector-specific risks such as market volatility and economic downturns. These external factors can significantly impact property values, occupancy rates, and rental income.
  3. Competitive Landscape within the Real Estate Industry: Gyrodyne faces potential difficulties in maintaining its competitive position, particularly against larger, more diversified real estate investment trusts (REITs). Its lack of consistent revenue growth and operational metrics may hinder its ability to compete effectively in the market.

AI Analysis | Feedback

null

AI Analysis | Feedback

Gyrodyne (NASDAQ: GYRO) operates as a real estate investment trust (REIT) primarily focusing on commercial properties within the New York metropolitan area, with a particular emphasis on medical office and industrial real estate.

The addressable markets for Gyrodyne's main products and services are as follows:

  • Industrial Real Estate Market (New York Metropolitan Area, particularly Long Island): The New York City industrial market alone encompassed 158.9 million square feet of existing industrial space as of the second quarter of 2023. The Long Island industrial sector has shown significant activity, with 1.1 million square feet leased in the second quarter of 2023, nearly doubling the five-year quarterly average for the region. In early 2025, Long Island's industrial real estate was noted as the strongest performer, with rental rates surging and vacancy rates plummeting to 3.2% in key logistics hubs within Suffolk County. As of the third quarter of 2025, industrial vacancy on Long Island was 6.1%, with year-to-date Class A leasing totaling 344,979 square feet.
  • Medical Office Real Estate Market (New York Metropolitan Area): Gyrodyne currently owns and manages approximately 50,000 square feet of medical office space in the suburbs of New York City. While specific overall market sizes for medical office space in the entire New York metropolitan area are not readily available, there is significant development activity. For instance, Gyrodyne's proposed Cortlandt Manor Medical Oriented District (MOD) plans for at least 80,000 square feet of Class A medical office space. Additionally, in Suffolk County, 45,000 square feet of lab space (a related but distinct category) is under construction near Stony Brook University.
  • Age-Restricted Residential Community Development (Long Island, New York): null

AI Analysis | Feedback

Gyrodyne (symbol: GYRO) is a real estate company operating with a strategic focus on the liquidation and monetization of its property portfolio to maximize shareholder value. As such, the expected drivers of future revenue growth over the next 2-3 years are tied to the successful execution of this strategy rather than traditional recurring revenue streams.

  1. Strategic Property Sales: The primary driver of future revenue for Gyrodyne will be the successful sale of its real estate assets. The company's financial statements are prepared on a liquidation basis, reflecting its plan to sell properties and distribute the proceeds to shareholders. Recent developments include an agreement to sell a 49-acre parcel in Smithtown, New York, demonstrating active progress in this core strategy.
  2. Value Enhancement through Entitlements and Development Flexibility: Gyrodyne actively seeks to enhance the value of its properties by pursuing entitlements and favorable zoning changes. This includes efforts for its Flowerfield and Cortlandt Manor properties to increase development flexibility. Successfully securing these approvals significantly boosts the marketability and potential sale price of its land holdings.
  3. Effective Management of Litigation: Ongoing legal matters, such as the Article 78 proceeding related to the Flowerfield property, can impact the timeline and realized value from property sales. Favorable resolution or successful defense against such litigation is crucial for removing impediments to the liquidation process and protecting asset values, thereby indirectly driving revenue growth through unimpeded sales.
  4. Strategic Management and Capital Improvements of Real Estate Portfolio: While in liquidation, Gyrodyne's approach involves managing its diversified portfolio of office, industrial, and service-oriented properties in the New York metropolitan area. This includes investing in targeted capital improvements and securing long-term leases with creditworthy tenants to enhance asset value and maintain a resilient revenue base until properties are sold. These actions aim to maximize the sale price when properties are eventually divested.
  5. Leveraging Local Market Knowledge and Zoning Expertise: The company leverages its deep ties to the Long Island region, local market knowledge, and zoning expertise to support its development initiatives. This expertise is critical for successful entitlement efforts and repositioning its assets for optimal outcomes, directly contributing to higher realized values from property sales.

AI Analysis | Feedback

Share Issuance

  • In March 2024, Gyrodyne completed an oversubscribed rights offering, which generated approximately $4.4 million in net proceeds. These funds were intended to support entitlement efforts, litigation costs, and general working capital.
  • Gyrodyne announced in November 2023 that it anticipated receiving $1,979,165 in funding through the issuance of common shares.

Capital Expenditures

  • Gyrodyne's strategy centers on enhancing the value of its properties in Flowerfield and Cortlandt Manor by pursuing entitlements to increase development flexibility, which involves associated costs.
  • For the year ended December 31, 2023, the company incurred approximately $449,000 in land entitlement costs, primarily consisting of engineering costs, legal fees, and real estate taxes.
  • As of August 2025, Gyrodyne estimates it may incur approximately $1.274 million in additional land entitlement costs through 2027 as part of its entitlement efforts.

Better Bets than Gyrodyne (GYRO)

Latest Trefis Analyses

TitleTopic
0DASHBOARDS 
1How Low Can Gyrodyne Stock Really Go?Return
Title
0ARTICLES

Trade Ideas

Select ideas related to GYRO. For more, see Trefis Trade Ideas.

Unique Key

Recent Active Movers

More From Trefis

Peer Comparisons for Gyrodyne

Peers to compare with:

Financials

GYROWELLVTRMPWOHISBRAMedian
NameGyrodyne WelltowerVentas Medical .Omega He.Sabra He. 
Mkt Price9.06188.2576.935.3344.5619.4131.98
Mkt Cap0.0126.635.13.213.24.78.9
Rev LTM59,7525,5559341,1507451,042
Op Inc LTM-31,580818499718267608
FCF LTM-22,746968147877341609
FCF 3Y Avg492,065687334723313511
CFO LTM-22,7871,549147877341609
CFO 3Y Avg492,1131,297334723313529

Growth & Margins

GYROWELLVTRMPWOHISBRAMedian
NameGyrodyne WelltowerVentas Medical .Omega He.Sabra He. 
Rev Chg LTM-1.2%32.6%15.7%45.6%13.7%8.9%14.7%
Rev Chg 3Y Avg2.1%20.9%10.7%-6.8%6.3%7.8%7.0%
Rev Chg Q-1.8%30.7%20.4%5.2%12.9%6.8%9.8%
QoQ Delta Rev Chg LTM-0.2%6.8%4.8%1.3%3.2%1.6%2.4%
Op Mgn LTM-50.0%16.2%14.7%53.5%62.4%35.8%26.0%
Op Mgn 3Y Avg-153.7%15.1%12.0%32.8%54.3%35.5%23.9%
QoQ Delta Op Mgn LTM2.6%0.7%0.0%15.0%0.1%-1.3%0.4%
CFO/Rev LTM-43.8%28.6%27.9%15.8%76.2%45.8%28.2%
CFO/Rev 3Y Avg1,138.1%26.8%26.3%34.4%71.6%45.2%39.8%
FCF/Rev LTM-43.8%28.2%17.4%15.8%76.2%45.8%22.8%
FCF/Rev 3Y Avg1,136.7%26.1%13.8%34.4%71.6%45.2%39.8%

Valuation

GYROWELLVTRMPWOHISBRAMedian
NameGyrodyne WelltowerVentas Medical .Omega He.Sabra He. 
Mkt Cap0.0126.635.13.213.24.78.9
P/S0.213.06.33.411.56.26.3
P/EBIT-0.584.343.91.516.716.116.4
P/E25.1131.8147.4-4.524.526.625.9
P/CFO-0.545.422.721.715.013.618.4
Total Yield4.0%0.8%3.0%-16.0%9.9%9.9%3.5%
Dividend Yield0.0%0.0%2.3%6.0%5.8%6.1%4.1%
FCF Yield 3Y Avg3,536.9%2.6%2.6%12.2%7.2%8.0%7.6%
D/E13.90.10.43.00.40.60.5
Net D/E3.50.10.42.90.30.50.4

Returns

GYROWELLVTRMPWOHISBRAMedian
NameGyrodyne WelltowerVentas Medical .Omega He.Sabra He. 
1M Rtn-4.3%-1.2%-1.7%5.8%0.0%1.1%-0.6%
3M Rtn-9.4%9.7%12.4%3.0%13.0%12.1%10.9%
6M Rtn6.3%20.5%19.0%34.5%21.3%9.8%19.7%
12M Rtn0.0%51.0%36.1%41.2%27.8%23.6%32.0%
3Y Rtn6.6%184.1%73.7%-45.1%101.0%88.3%81.0%
1M Excs Rtn-3.6%-0.6%-2.0%3.1%-0.1%-0.3%-0.4%
3M Excs Rtn-13.6%7.4%9.6%-0.4%9.9%7.6%7.5%
6M Excs Rtn-4.2%9.9%8.4%23.9%10.7%-0.8%9.2%
12M Excs Rtn-18.7%33.7%17.7%26.9%9.8%6.4%13.7%
3Y Excs Rtn-71.4%113.8%0.0%-121.0%21.8%12.6%6.3%

Financials

Segment Financials

Assets by Segment
$ Mil2014
Single Segment48
Total48


Price Behavior

Price Behavior
Market Price$9.06 
Market Cap ($ Bil)0.0 
First Trading Date08/18/1995 
Distance from 52W High-15.6% 
   50 Days200 Days
DMA Price$9.68$8.68
DMA Trendupdown
Distance from DMA-6.4%4.4%
 3M1YR
Volatility31.0%65.0%
Downside Capture22.2850.47
Upside Capture-61.0038.57
Correlation (SPY)2.4%4.0%
GYRO Betas & Captures as of 12/31/2025

 1M2M3M6M1Y3Y
Beta0.610.210.04-0.060.100.01
Up Beta1.280.720.121.820.08-0.08
Down Beta1.601.120.68-0.200.170.02
Up Capture-16%-55%-42%-31%4%2%
Bmk +ve Days11233772143431
Stock +ve Days24103556163
Down Capture44%7%-12%-104%13%9%
Bmk -ve Days11182755108320
Stock -ve Days411173862181

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
 GYRO vs. Other Asset Classes (Last 1Y)
 GYROSector ETFEquityGoldCommoditiesReal EstateBitcoin
Annualized Return0.0%8.1%20.0%71.6%5.6%10.4%1.0%
Annualized Volatility64.8%16.6%19.3%20.0%15.3%16.7%34.5%
Sharpe Ratio0.250.300.822.590.150.420.11
Correlation With Other Assets 4.6%7.1%1.3%-0.8%6.6%-1.1%

ETFs used for asset classes: Sector ETF = XLRE, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
 GYRO vs. Other Asset Classes (Last 5Y)
 GYROSector ETFEquityGoldCommoditiesReal EstateBitcoin
Annualized Return-11.0%6.6%14.6%18.8%11.6%5.8%21.0%
Annualized Volatility58.7%19.0%17.1%15.6%18.7%18.8%48.2%
Sharpe Ratio-0.100.250.690.970.500.220.46
Correlation With Other Assets 6.8%7.2%2.4%-1.2%7.6%0.2%

ETFs used for asset classes: Sector ETF = XLRE, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
 GYRO vs. Other Asset Classes (Last 10Y)
 GYROSector ETFEquityGoldCommoditiesReal EstateBitcoin
Annualized Return-5.9%6.4%15.1%15.1%7.6%5.4%71.7%
Annualized Volatility40.3%20.6%18.0%14.8%17.6%20.8%55.7%
Sharpe Ratio-0.050.270.720.840.350.230.92
Correlation With Other Assets 1.7%0.4%-1.7%-0.9%1.9%0.3%

ETFs used for asset classes: Sector ETF = XLRE, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date12312025
Short Interest: Shares Quantity47
Short Interest: % Change Since 12152025-9.6%
Average Daily Volume265
Days-to-Cover Short Interest1
Basic Shares Quantity142,871
Short % of Basic Shares0.0%

SEC Filings

Expand for More
Report DateFiling DateFiling
06/30/201508/14/201510-Q (06/30/2015)
03/31/201505/15/201510-Q (03/31/2015)
12/31/201403/31/201510-K (12/31/2014)
09/30/201411/05/201410-Q (09/30/2014)
06/30/201408/08/201410-Q (06/30/2014)
03/31/201405/12/201410-Q (03/31/2014)
12/31/201303/25/201410-K (12/31/2013)
09/30/201311/12/201310-Q (09/30/2013)
06/30/201308/09/201310-Q (06/30/2013)
03/31/201305/10/201310-Q (03/31/2013)
12/31/201203/18/201310-K (12/31/2012)
09/30/201211/14/201210-Q (09/30/2012)
06/30/201208/13/201210-Q (06/30/2012)
09/30/201111/09/201110-Q (09/30/2011)
06/30/201108/12/201110-Q (06/30/2011)
03/31/201105/12/201110-Q (03/31/2011)